SCHEMBL31023973

SCHEMBL31023973

O=C(On1nnc2cccnc21)N1CCN(C(c2ccc3c(c2)COCO3)c2ccc3c(c2)COCO3)CC1

nearest known ligand 0.46

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ MGLL Q99685 9/20 0.46
▸ FAAH O00519 5/20 0.46
▸ PLA2G7 Q13093 1/20 0.33
▸ ABHD6 Q9BV23 1/20 0.33
▸ KRAS P01116 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.32
▸ NPSR1 Q6W5P4 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ USP2 O75604 1/20 0.31
▸ OGA O60502 1/20 0.31
▸ SMAD3 P84022 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31023761 0.87 MGLL (0.44) MGLLFAAHALDH1A1KMT2A
SCHEMBL31023778 0.87 MGLL (0.44) MGLLFAAHALDH1A1KMT2A
SCHEMBL31023880 0.86 MGLL (0.64) MGLLFAAHALDH1A1KMT2A
SCHEMBL31023694 0.79 MGLL (0.35) MGLLFAAHPLA2G7ABHD6MAPK1
SCHEMBL31023695 0.79 MGLL (0.42) MGLLFAAHALDH1A1NPSR1MEN1
SCHEMBL31023763 0.77 MGLL (0.59) MGLLPLA2G7ABHD6ALDH1A1MEN1
SCHEMBL31023681 0.76 MGLL (0.63) MGLLFAAHKMT2A
SCHEMBL31023668 0.76 MGLL (0.65) MGLLFAAHALDH1A1NPSR1KMT2A
SCHEMBL31023723 0.74 SMAD3 (0.42) MGLLALDH1A1NPSR1MEN1KMT2A
SCHEMBL31023944 0.74 SCD5 (0.44) MGLLPLA2G7ABHD6ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof APOGEE PHARMACEUTICALS, INC. (CA) 2025-08-05 — — US claimed
EP-4665718-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF Apogee Pharmaceuticals, Inc. (CA) 2025-12-24 — — EP disclosed
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof APOGEE PHARMACEUTICALS, INC. (CA) 2025-08-05 — — US disclosed
US-20240294514-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2024-09-05 — — US disclosed
WO-2024168426-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2024-08-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof MGLL, PNLIP, LPL MGLL 1/4885FAAH 12/4885PLA2G7 72/4885
US-20240294514-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF MGLL, PNLIP, LPL MGLL 1/4885FAAH 12/4885PLA2G7 72/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback